The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3
Abstract
OBJECTIVE: The ARBITER 2 trial showed that extended-release niacin (ERN) when added to statin monotherapy slowed the progression of carotid atherosclerosis over 12 months. Whether longer treatment with ERN would have a greater effect on carotid intima-media thickness (CIMT) is unknown. RESEARCH DESIGN AND METHODS: We examined the long-term effects of ERN on high density lipoprotein (HDL-C) cholesterol and CIMT during 12-24 months treatment with ERN in ARBITER 2 participants who were either continued or were crossed over (from placebo) to ERN 1000 mg daily. MAIN OUTCOME MEASURES: Among 149 subjects completing ARBITER 2, 130 (88%) enrolled in ARBITER 3. The prespecified primary endpoints were the within-group change in CIMT and HDL-C in patients receiving placebo for 12 months (n = 71), ERN for 12 months (comprised of subjects from ERN treatment during ARBITER 2 (n = 78) and those crossed over to ERN from placebo after ARBITER 2 (n = 47)), and ERN for 24 months spanning ARBITER 2 and 3 (n = 57). Five subjects discontinued the study due to flushing side effects. The study was completed by 104 subjects (47 crossed over from placebo; 57 with ERN continued from ARBITER 2). RESULTS: HDL-C increased in the ERN group from 39.5 +/- 6.7 to 48.6 +/- 13.3 mg/dl (p < 0.001) along with modest reductions in LDL-C and TG. Among 125 participants treated with ERN for 12 months, there was a net regression of CIMT of -0.027 +/- 0.011 mm (p < 0.001 vs. placebo). Among 57 participants treated with ERN for 24 months, there was additional significant regression of CIMT of -0.041 +/- 0.021 mm (p = 0.001 vs. placebo). Controlling for changes in LDL and triglycerides, only changes in HDL-C were independently associated with regression of CIMT (beta = -0.25; p = 0.001). CONCLUSION: When added to statin therapy, ERN significantly increases HDL-C and induces atherosclerosis regression measured by CIMT over 24 months. Limitations to this study include its open-label design and the inability to relate CIMT effects to clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Hodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., & Azen, S. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00002 · Cited by 1,217
(1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.6.1071 · Cited by 1,137
Wang, N., Lan, D., Chen, W., Matsuura, F., & Tall, A. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403506101 · Cited by 1,061
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
Self-citationTaylor, A. J., Kent, S. M., Flaherty, P. J., Coyle, L. C., Markwood, T. T., & Vernalis, M. N. (2002) · Circulation · doi:10.1161/01.cir.0000034508.55617.65 · Cited by 558
Self-citationHDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study
Després, J.-P., Lemieux, I., Dagenais, G.-R., Cantin, B., & Lamarche, B. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00603-1 · Cited by 316
Kashyap, M. L., McGovern, M. E., Berra, K., Guyton, J. R., Kwiterovich, P. O., Harper, W. L., Toth, P. D., Favrot, L. K., Kerzner, B., Nash, S. D., et al. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02338-4 · Cited by 235
Whitney, E. J., Krasuski, R. A., Personius, B. E., Michalek, J. E., Maranian, A. M., Kolasa, M. W., Monick, E., Brown, B. G., & Gotto, A. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-2-200501180-00008 · Cited by 233
Guyton, J. R., Goldberg, A. C., Kreisberg, R. A., Sprecher, D. L., Superko, H. R., & O’Connor, C. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00448-2 · Cited by 206
Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198
van Dam, M. J., de Groot, E., Clee, S. M., Hovingh, G. K., Roelants, R., Brooks-Wilson, A., Zwinderman, A. H., Smit, A. J., Smelt, A. H., Groen, A. K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07277-x · Cited by 198
The nicotinic acid receptor–a new mechanism for an old drug
Karpe, F., & Frayn, K. N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16359-9 · Cited by 185
Brewer, H. B., Remaley, A. T., Neufeld, E. B., Basso, F., & Joyce, C. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000142804.27420.5b · Cited by 182
Nicholls, S. J., Cutri, B., Worthley, S. G., Kee, P. H., Rye, K.-A., Bao, S., & Barter, P. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000184760.95957.d6 · Cited by 156
von Birgelen, C., Hartmann, M., Mintz, G. S., van Houwelingen, K. G., Deppermann, N., Schmermund, A., Böse, D., Eggebrecht, H., Neumann, T., Gössl, M., et al. (2004) · Circulation · doi:10.1161/01.cir.0000142048.94084.ca · Cited by 152
Change in α 1 HDL Concentration Predicts Progression in Coronary Artery Stenosis
Asztalos, B. F., Batista, M. C., Horvath, K. V., Cox, C. E., Dallal, G. E., Morse, J. S., Brown, G. B., & Schaefer, E. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000066133.32063.bb · Cited by 137
Elevated High-Density Lipoprotein Cholesterol Levels Are Protective Against Plaque Progression
Johnsen, S. H., Mathiesen, E. B., Fosse, E., Joakimsen, O., Stensland-Bugge, E., Njølstad, I., & Arnesen, E. (2005) · Circulation · doi:10.1161/circulationaha.104.522706 · Cited by 105
Influence of baseline lipids on effectiveness of pravastatin in the CARE trial
Pfeffer, M. A., Sacks, F. M., Moyé, L. A., East, C. A., Goldman, S. M., Nash, D. T., Rouleau, J. R., Rouleau, J. L., Sussex, B. A., Théroux, P., et al. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00522-1 · Cited by 93
Smilde, T. J., Wollersheim, H. C. H., van Langen, H., & Stalenhoef, A. F. H. (1997) · Clinical Science · doi:10.1042/cs0930317 · Cited by 62
The IDEAL Cholesterol: Lower Is Better
Cannon, C. P. (2005) · JAMA · doi:10.1001/jama.294.19.2492 · Cited by 55
Influence of HDL Cholesterol on Preclinical Carotid Atherosclerosis in Familial Hypercholesterolemia
Junyent, M., Cofán, M., Núñez, I., Gilabert, R., Zambón, D., & Ros, E. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000218507.95149.42 · Cited by 55
Cited by
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., Weissman, N. J., & Turco, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 644
Self-citationJellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Metadata
- Authors
- Taylor, A. J., Lee, H. J., & Sullenberger, L. E.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2006-10-12
- Volume
- 22
- Issue
- 11
- Pages
- 2243-2250
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W1980946271
- Cited by
- 304
- References
- 31
- FWCI
- 34.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.